Skip to content

Physical Disability and Psychedelic Therapies: An Agenda for Inclusive Research and Practice

Kevin Mintz, Brinn Gammer, Amanda Khan, Gretchen Shaub, Steven R. Levine, Dominic Sisti

Frontiers in Psychiatry May 25, 2022 DOI: 10.3389/fpsyt.2022.914458 via OpenAlex

Summary

AI-generated from the abstract

Clinical trials for psychedelic therapies have increased but often exclude individuals with physical and sensory disabilities, risking structural ableism. Drawing on disability studies and medical ethics, the authors recommend prioritizing inclusion, providing accommodations, training facilitators in disability awareness, and practicing cultural humility. These steps aim to address mental health burdens faced by disability communities and spur further debate on accessibility.

Study at a glance

Characteristics Theoretical or philosophical paper Peer reviewed
Keywords Inclusion mineral Mental health Scholarship Ableism Learning disability
Citations 13
Key finding Psychedelic research organizations should prioritize inclusion of individuals with physical and sensory disabilities to avoid reinforcing structural ableism in healthcare.

Abstract

Over the past decade, there has been an increase in the number of clinical trials for psychedelic therapies as treatments for a wide range of psychiatric conditions. We are concerned that research organizations overseeing these trials have neglected the inclusion of individuals with physical and sensory disabilities. We suggest that psychedelic research organizations should prioritize and plan for the inclusion of individuals with physical and sensory disabilities to address the mental health burdens they confront. Not doing so risks reinforcing structural ableism in healthcare: the discriminatory manifestation of lowered expectations toward people with disabilities on the part of medical providers. Drawing on scholarship from disability studies and medical ethics, we offer four recommendations for disability inclusion in research. We recognize particular populations shoulder significant mental health burdens; these populations deserve priority and should be given a range of accommodations. We emphasize the need for extensive disability awareness training for those facilitating psychedelic therapies and encourage psychedelic researchers and therapists to exercise cultural humility toward individuals with physical and sensory disabilities. This article should be the impetus for further scholarship and debate about how psychedelic research and therapies can be made accessible to members of disability communities who might benefit.

Comments

No comments yet.

Log in to comment